Nilotinib Pharmascience

Nilotinib, the active ingredient in Nilotinib Pharmascience, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively inhibits the BCR‑ABL kinase and is indicated for the treatment of chronic myeloid leukemia in adult patients.

GNH USA supplies Nilotinib Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is employed in the management of BCR‑ABL positive leukemias, primarily chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): improves disease control and prolongs survival. - Chronic myeloid leukemia (accelerated phase): helps achieve hematologic and cytogenetic responses. - Chronic myeloid leukemia (blast phase): provides targeted therapy when combined with other agents.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Rash: skin erythema or maculopapular eruptions. - Elevated liver enzymes: increased ALT/AST levels. - Fatigue: general tiredness or weakness. - Myalgia: muscle aches or discomfort.

Serious or Rare Side Effects: - Cardiovascular events: arterial occlusive disease or ischemic heart disease. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Severe hepatic injury: marked elevation of liver enzymes or jaundice. - QT interval prolongation: risk of cardiac arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia, thrombocytopenia, or anemia.

When prescribing or dispensing Nilotinib, consider the following safety measures.

- Cardiac monitoring: assess baseline ECG and monitor QT interval during therapy. - Liver function: evaluate hepatic enzymes before initiation and periodically thereafter. - Pancreatic enzymes: check amylase and lipase levels regularly. - Drug interactions: review concomitant medications that may affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless clearly justified. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Nilotinib interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Nilotinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase risk of toxicity. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower absorption; separate dosing by at least 2 hours. - Proton‑pump inhibitors: potential reduction in bioavailability; monitor therapeutic response. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased plasma levels; consider dose adjustment. - Herbal supplements (e.g., St. John's wort): possible induction of CYP3A4, reducing efficacy. - Vaccines: live attenuated vaccines should be avoided during treatment.